Opinion|Videos|January 15, 2025
Sequencing Therapies in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss second-line (2L) treatment strategies for lower-risk myelodysplastic syndrome (LR-MDS), focusing on how to choose a 2L treatment for patients refractory to first-line options, and provide an overview of recent updates from the IMerge trial (Santini et al, EHA 2024; Zeidan et al, JCO 2024), while considering the role of imetelstat in treatment sequencing according to NCCN Guidelines MDS-5.
Episodes in this series
- Please give an overview of 2L treatment strategies.
- If patients are refractory to the available 1L options, how would you choose a 2L treatment?
- Please give a brief overview of recent updates from IMerge (Santini et al, EHA 2024; Zeidan et al, JCO 2024).
- In your opinion, and considering NCCN Guidelines MDS-5, where do you see imetelstat in the treatment sequencing for LR-MDS?
- What can we learn from these studies and are there any remaining knowledge gaps to note?
Related Content
Advertisement
